1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
|
2. |
Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet, 2016, 388(10039): 73-85.
|
3. |
姚汝铖, 郑军, 邢荣春. 微小RNA在胰腺癌中的研究进展. 中国普外基础与临床杂志, 2012, 19(8): 911-915.
|
4. |
Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol, 2016, 8(1): 18-29.
|
5. |
Xu J, Cao Z, Liu W, et al. Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: a multicenter study. Ann Surg, 2016, 263(6): 1173-1179.
|
6. |
Qu K, Zhang X, Lin T, et al. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Sci Rep, 2017, 7(1): 1692.
|
7. |
Duell EJ, Lujan-Barroso L, Sala N, et al. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Int J Cancer, 2017, 141(5): 905-915.
|
8. |
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 2008, 3(6): 1101-1108.
|
9. |
de la Santa LG, Retortillo JA, Miguel AC, et al. Radiology of pancreatic neoplasms: an update. World J Gastrointest Oncol, 2014, 6(9): 330-343.
|
10. |
Pietryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol, 2015, 6(4): 343-357.
|
11. |
Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol, 2012, 3(2): 105-119.
|
12. |
Decker GA, Batheja MJ, Collins JM, et al. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y), 2010, 6(4): 246-254.
|
13. |
Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol, 2010, 21(3): 441-447.
|
14. |
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol, 2007, 33(3): 266-270.
|
15. |
Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer, 2013, 108(2): 361-369.
|
16. |
Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA, 2014, 311(4): 392-404.
|
17. |
Meng QC, Qiu WW, Wen ZQ, et al. Novel blood-based microRNA biomarkers for diagnosis of pancreatic cancer: a meta-analysis. Tumori, 2015, 101(2): 199-205.
|
18. |
Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem, 2012, 58(3): 610-618.
|
19. |
Frampton AE, Giovannetti E, Jamieson NB, et al. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn, 2014, 14(3): 267-271.
|
20. |
Abue M, Yokoyama M, Shibuya R, et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol, 2015, 46(2): 539-547.
|
21. |
du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem, 2010, 56(4): 603-612.
|
22. |
Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila), 2009, 2(9): 807-813.
|
23. |
Cote GA, Gore AJ, McElyea SD, et al. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol, 2014, 109(12): 1942-1952.
|
24. |
Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res, 2010, 16(16): 4246-4255.
|
25. |
Ryu JK, Hong SM, Karikari CA, et al. Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology, 2010, 10(1): 66-73.
|